Edition:
United Kingdom

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

4.97USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$4.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
64,740
52-wk High
$11.25
52-wk Low
$4.07

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences Collaborates With Pfizer To Evaluate Cancer Drugs
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES ANNOUNCES CLINICAL TRIAL COLLABORATION TO EVALUATE IBRANCE® (PALBOCICLIB) AND TALAZOPARIB IN COMBINATION WITH CB-839.CALITHERA BIOSCIENCES-TRIAL COLLABORATIONS TO EVALUATE PFIZER'S PALBOCICLIB & TALAZOPARIB, EACH IN COMBINATION WITH CO'S GLUTAMINASE INHIBITOR CB-839.CALITHERA BIOSCIENCES - AS PART OF COLLABORATION, PFIZER WILL PROVIDE PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL SUPPORT.CALITHERA BIOSCIENCES - TO INITIATE PHASE 1/2 CLINICAL TRIAL OF COMBINATION OF CB-839 PLUS TALAZOPARIB IN PATIENTS WITH RCC, AND TNBC IN Q1 OF 2019.  Full Article

Calithera Biosciences Q2 Operating Loss Per Share $0.09
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 OPERATING LOSS PER SHARE $0.09.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.Q2 REVENUE $17.1 MILLION VERSUS $7.3 MILLION.Q2 REVENUE VIEW $6.1 MILLION -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $152.2 MILLION AT JUNE 30, 2018..  Full Article

Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Calithera Biosciences Inc :Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting.Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​.Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​.Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​.Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​.Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​.Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​.  Full Article

Calithera Biosciences Q3 operating loss per share $0.17
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Calithera Biosciences Inc :Calithera biosciences reports third quarter 2017 financial results and recent highlights.Q3 operating loss per share $0.17.Q3 revenue $7.3 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.5 million -- Thomson Reuters I/B/E/S.Calithera biosciences inc - ‍as of september 30, 2017, cash, cash equivalents and investments totaled $196.5 million​.Calithera biosciences inc - qtrly ‍research and development expenses were $10.8 million compared with $6.3 million for same period in prior year​.  Full Article

Hawkes Bay Master Investors (Cayman) L.P. reports 5.28 pct passive stake in Calithera Biosciences Inc
Monday, 6 Mar 2017 

Calithera Biosciences Inc :Hawkes Bay Master Investors (Cayman) L.P. reports 5.28 percent passive stake in Calithera Biosciences Inc as on February 22, 2017 - SEC filing.  Full Article

Calithera Biosciences says CFO William Waddill has resigned
Monday, 12 Dec 2016 

Calithera Biosciences Inc : Calithera biosciences - William Waddill has resigned as company's senior vice president and chief financial officer .Waddill's resignation will be effective on or about December 31, 2016.  Full Article